- Home
- DNTH vs SKT Comparison
DNTH vs SKT Comparison
Compare DNTH & SKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DNTH | SKT |
|---|---|---|
| Founded | 2015 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.2B |
| IPO Year | 2018 | 1994 |
Fundamental Metrics
Financial Performance| Metric | DNTH | SKT |
|---|---|---|
| Price | $88.51 | $36.20 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 6 |
| Target Price | ★ $121.00 | $37.17 |
| AVG Volume (30 Days) | 523.2K | ★ 639.1K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 3.18% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.71 |
| Revenue | ★ $2,036,000.00 | N/A |
| Revenue This Year | N/A | $0.37 |
| Revenue Next Year | $29.48 | $3.90 |
| P/E Ratio | ★ N/A | $51.04 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.77 | $28.69 |
| 52 Week High | $96.50 | $37.95 |
Technical Indicators
Market Signals| Indicator | DNTH | SKT |
|---|---|---|
| Relative Strength Index (RSI) | 56.27 | 50.10 |
| Support Level | $33.94 | $31.59 |
| Resistance Level | $96.50 | $37.28 |
| Average True Range (ATR) | 4.02 | 0.63 |
| MACD | -1.21 | -0.08 |
| Stochastic Oscillator | 45.82 | 25.17 |
Price Performance
Historical ComparisonAbout DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
About SKT Tanger Inc.
Tanger Inc is an owner and operator of outlet and open-air centers in the United States and Canada. It is a fully-integrated, self-administered and self-managed REIT, which focuses on developing, acquiring, owning, operating and managing outlet and open-air shopping centers. Its consolidated portfolio consisted of 31 outlet centers and 2 open-air lifestyle centers.